Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-04-25 @ 5:14 PM
Study NCT ID:
NCT03273660
Status:
COMPLETED
Last Update Posted:
2018-07-27
First Post:
2017-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)
Sponsor:
Derming SRL
Organization:
Study Overview
Official Title:
Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to aging mechanism.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: